Comparative Pharmacology
Head-to-head clinical analysis: SODIUM CHROMATE CR 51 versus THALLOUS CHLORIDE TL 201.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SODIUM CHROMATE CR 51 versus THALLOUS CHLORIDE TL 201.
SODIUM CHROMATE CR 51 vs THALLOUS CHLORIDE TL 201
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Radiolabeled sodium chromate (51Cr) binds to red blood cells, tagging them for survival studies. 51Cr emits gamma radiation, allowing detection and quantification of RBC mass and survival via scintillation counting or imaging.
Thallous chloride Tl-201 is a potassium analog that is taken up by viable myocardial cells via the Na+/K+ ATPase pump. Its distribution reflects regional myocardial blood flow and cell viability. In areas of ischemia or infarction, uptake is reduced, creating a perusion defect.
Intravenous injection, 5-30 microcuries (0.185-1.11 MBq) as a single dose.
111-148 MBq (3-4 mCi) intravenous injection for myocardial perfusion imaging; imaging begins 5-10 minutes post-injection.
None Documented
None Documented
The biological half-life is approximately 27–30 days. Clinically, gradual clearance from blood and tissues occurs over weeks to months.
Terminal elimination half-life: approximately 73 hours. Clinical context: The long half-life allows for delayed imaging (e.g., redistribution imaging for thallium-201 myocardial perfusion scans).
Primarily renal. Approximately 90% of absorbed dose is excreted in urine within 48 hours. Fecal excretion accounts for less than 5%.
Renal: approximately 70% over 10 days; fecal: less than 30% over 10 days.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical